Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPFIT-CIN Study
PACTR202505720883384Phase 2Not yet recruiting
- Sponsor
- University of Lagos
- Start
- Jun 2025
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil and imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by University of Lagos. Primary endpoint: Complete regression of CIN2/3 lesions at 3 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
fluorouracilimiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on PACTR202505720883384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505720883384.